Skip to main content
Top
Published in: Trials 1/2022

01-12-2022 | Neurogenic Bladder | Study protocol

Establishing a core outcome set for neurogenic bladder trials: study protocol for a scoping review and Delphi surveys

Authors: Yan Zhang, Yamin Chen, Mingming Niu, Yuanyuan Li, Jiaoyan Zhang, Li Zhang, Fangfang Wu, Qingyun Chen, Huijin Yu, Jinhui Tian

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Neurogenic bladder (NGB) is a chronic and disabling condition with a high prevalence rate, which can cause economic burden on patients and their families and reduce the quality of life of patients. Researchers have carried out a large number of clinical trials on the effectiveness and safety of different interventions for the treatment of NGB. The published clinical trials of NGB generally suffered from inconsistent and irregular reporting of outcome indicators. To facilitate future research studies of NGB, a core outcome set (COS) is required, which helps translate the results into high-quality evidence.

Methods and analysis

This mixed-method project has four phases instrument: in phase 1, a scoping review of the literature to identify outcomes that have been reported in clinical trials and systematic reviews of clinical trials of interventions for NGB; in phase 2, a qualitative component using interviews to obtain the views of NGB patients, families, and their caregivers; in phase 3, Delphi survey among stakeholders to prioritize the core outcomes; and in phase 4, a face-to-face consensus meeting to discuss and agree on the final NBG COS.

Conclusions

We will develop a COS that should be reported in future clinical trials of NGB.

Trial registration

Core Outcome Measures in Effectiveness Trials (COMET) Initiative database registration: http://​www.​comet-initiative.​org/​studies/​details/​1985. Registered on 02 January 2022. INPLASY INPLASY202210007​
Literature
1.
go back to reference Przydacz M, Denys P, Corcos J. What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? Ann Phys Rehabil Med. 2017;60(5):341–6.CrossRef Przydacz M, Denys P, Corcos J. What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? Ann Phys Rehabil Med. 2017;60(5):341–6.CrossRef
2.
go back to reference Tractenberg RE, Frost JK, Yumoto F, Rounds AK, Ljungberg IH, Groah SL. Validity of the urinary symptom questionnaires for people with neurogenic bladder (USQNB) who void or use indwelling catheters. Spinal Cord. 2021;59(9):948–58.CrossRef Tractenberg RE, Frost JK, Yumoto F, Rounds AK, Ljungberg IH, Groah SL. Validity of the urinary symptom questionnaires for people with neurogenic bladder (USQNB) who void or use indwelling catheters. Spinal Cord. 2021;59(9):948–58.CrossRef
3.
go back to reference Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395–401.CrossRef Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395–401.CrossRef
4.
go back to reference Denys P, Chartier-Kastler E, Even A, Joussain C. How to treat neurogenic bladder and sexual dysfunction after spinal cord lesion. Rev Neurol. 2021;177(5):589–93.CrossRef Denys P, Chartier-Kastler E, Even A, Joussain C. How to treat neurogenic bladder and sexual dysfunction after spinal cord lesion. Rev Neurol. 2021;177(5):589–93.CrossRef
5.
go back to reference Kabra AT, Feustel PJ, Kogan BA. Screening for depression and anxiety in childhood neurogenic bladder dysfunction. J Pediatr Urol. 2015;11(2):75.e71–7.CrossRef Kabra AT, Feustel PJ, Kogan BA. Screening for depression and anxiety in childhood neurogenic bladder dysfunction. J Pediatr Urol. 2015;11(2):75.e71–7.CrossRef
6.
go back to reference Tate DG, Rohn EJ, Forchheimer M, Walsh S, DiPonio L, Rodriguez GM, et al. Factors influencing decisions about neurogenic bladder and bowel surgeries among veterans and civilians with spinal cord injury. J Spinal Cord Med. 2021:1–16. Online ahead of print. Tate DG, Rohn EJ, Forchheimer M, Walsh S, DiPonio L, Rodriguez GM, et al. Factors influencing decisions about neurogenic bladder and bowel surgeries among veterans and civilians with spinal cord injury. J Spinal Cord Med. 2021:1–16. Online ahead of print.
7.
go back to reference Pelosi G, Faleiros F, Pereira MRC, Bimbatti KF, Tholl AD. Study on the prevalence of neurogenic bladder in Brazilians with traumatic and non-traumatic spinal cord injury. J Spinal Cord Med. 2021:1–5. Online ahead of print. Pelosi G, Faleiros F, Pereira MRC, Bimbatti KF, Tholl AD. Study on the prevalence of neurogenic bladder in Brazilians with traumatic and non-traumatic spinal cord injury. J Spinal Cord Med. 2021:1–5. Online ahead of print.
8.
go back to reference Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19(10 Suppl):s191–6.PubMed Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19(10 Suppl):s191–6.PubMed
9.
go back to reference Kim M, Harvey J, Gusev A, Norton JM, Miran S, Bavendam T. A scoping review of the economic burden of non-cancerous genitourinary conditions. Urology. 2021. Online ahead of print. Kim M, Harvey J, Gusev A, Norton JM, Miran S, Bavendam T. A scoping review of the economic burden of non-cancerous genitourinary conditions. Urology. 2021. Online ahead of print.
10.
go back to reference Flack C, Powell CR. The worldwide economic impact of neurogenic bladder. Curr Bladder Dysfunct Rep. 2015;10(4):350–4.CrossRef Flack C, Powell CR. The worldwide economic impact of neurogenic bladder. Curr Bladder Dysfunct Rep. 2015;10(4):350–4.CrossRef
11.
go back to reference Silva T, T. Horliana AC, Malavazzi TCS, Santos EM, MLL G, KPS F, et al. Efficacy and safety of electrical stimulation in the treatment of neurogenic bladder dysfunction in myelomeningocele-systematic review of randomized clinical trials. Neurourol Urodyn. 2021;41(1):91–101. Silva T, T. Horliana AC, Malavazzi TCS, Santos EM, MLL G, KPS F, et al. Efficacy and safety of electrical stimulation in the treatment of neurogenic bladder dysfunction in myelomeningocele-systematic review of randomized clinical trials. Neurourol Urodyn. 2021;41(1):91–101.
12.
go back to reference Zhang D, Sun F, Yao H, Bao X, Wang D, Cui Y, et al. The efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:756582.CrossRef Zhang D, Sun F, Yao H, Bao X, Wang D, Cui Y, et al. The efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis. Front Pharmacol. 2021;12:756582.CrossRef
13.
go back to reference Zhu Z, Zhuo Y, Jin H, Wu B, Li Z. Chinese medicine therapies for neurogenic bladder after spinal cord injury: a protocol for systematic review and network meta-analysis. Medicine. 2021;100(37):e27215.CrossRef Zhu Z, Zhuo Y, Jin H, Wu B, Li Z. Chinese medicine therapies for neurogenic bladder after spinal cord injury: a protocol for systematic review and network meta-analysis. Medicine. 2021;100(37):e27215.CrossRef
14.
go back to reference Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.CrossRef Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.CrossRef
15.
go back to reference Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. Core outcome set-STAndards for eporting: the COS-STAR statement. PLoS Med. 2016;13(10):e1002148.CrossRef Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. Core outcome set-STAndards for eporting: the COS-STAR statement. PLoS Med. 2016;13(10):e1002148.CrossRef
16.
go back to reference Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core outcome set-STAndards for development: the COS-STAD recommendations. PLoS Med. 2017;14(11):e1002447.CrossRef Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core outcome set-STAndards for development: the COS-STAD recommendations. PLoS Med. 2017;14(11):e1002447.CrossRef
17.
go back to reference Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18(Suppl 3):280.CrossRef Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18(Suppl 3):280.CrossRef
18.
go back to reference van’t Hooft J, Alfirevic Z, Asztalos EV, Biggio JR, Dugoff L, Hoffman M, et al. CROWN initiative and preterm birth prevention: researchers and editors commit to implement core outcome sets. BJOG. 2018;125(1):8–11.CrossRef van’t Hooft J, Alfirevic Z, Asztalos EV, Biggio JR, Dugoff L, Hoffman M, et al. CROWN initiative and preterm birth prevention: researchers and editors commit to implement core outcome sets. BJOG. 2018;125(1):8–11.CrossRef
19.
go back to reference Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core outcome set-STAndardised protocol items: the COS-STAP statement. Trials. 2019;20(1):116.CrossRef Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core outcome set-STAndardised protocol items: the COS-STAP statement. Trials. 2019;20(1):116.CrossRef
20.
go back to reference Ooi CP, Yusof Khan AHK, Abdul Manaf R, Mustafa N, Sukor N, Williamson PR, et al. Study protocol to develop a core outcome set for thyroid dysfunction to bridge the unmet needs of patient-centred care. BMJ Open. 2021;11(7):e050231.CrossRef Ooi CP, Yusof Khan AHK, Abdul Manaf R, Mustafa N, Sukor N, Williamson PR, et al. Study protocol to develop a core outcome set for thyroid dysfunction to bridge the unmet needs of patient-centred care. BMJ Open. 2021;11(7):e050231.CrossRef
21.
go back to reference Zhang M, Chua HZ, Zhang J, Niu B, Zheng W, Li K, et al. Developing a core outcome set on traditional Chinese medicine (COS-TCM) for chronic heart failure (CHF): a study protocol. BMJ Open. 2021;11(7):e047148.CrossRef Zhang M, Chua HZ, Zhang J, Niu B, Zheng W, Li K, et al. Developing a core outcome set on traditional Chinese medicine (COS-TCM) for chronic heart failure (CHF): a study protocol. BMJ Open. 2021;11(7):e047148.CrossRef
22.
go back to reference D'Souza R, Villani L, Hall C, Seyoum M, Kingdom J, Krznaric M, et al. Core outcome set for studies on pregnant women with vasa previa (COVasP): a study protocol. BMJ Open. 2020;10(7):e034018.CrossRef D'Souza R, Villani L, Hall C, Seyoum M, Kingdom J, Krznaric M, et al. Core outcome set for studies on pregnant women with vasa previa (COVasP): a study protocol. BMJ Open. 2020;10(7):e034018.CrossRef
23.
go back to reference Evangelidis N, Sautenet B, Madero M, Tong A, Ashuntantang G, Sanabria LC, et al. Standardised outcomes in nephrology - chronic kidney disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials. 2021;22(1):612.CrossRef Evangelidis N, Sautenet B, Madero M, Tong A, Ashuntantang G, Sanabria LC, et al. Standardised outcomes in nephrology - chronic kidney disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials. 2021;22(1):612.CrossRef
24.
go back to reference Qiu R, Han S, Wei X, Zhong C, Li M, Hu J, et al. Development of a core outcome set for the benefits and adverse events of acute heart failure in clinical trials of traditional Chinese medicine and Western medicine: a study protocol. Front Med. 2021;8:677068.CrossRef Qiu R, Han S, Wei X, Zhong C, Li M, Hu J, et al. Development of a core outcome set for the benefits and adverse events of acute heart failure in clinical trials of traditional Chinese medicine and Western medicine: a study protocol. Front Med. 2021;8:677068.CrossRef
25.
go back to reference Xie Q, Deng X, Xiao J, Chen X, He Y, Yang L, et al. Protocol of the development of a core outcome set for ischemic stroke in clinical trials of Chinese medicine. Evid-based Complement Altern Med. 2020;2020:2649843. Xie Q, Deng X, Xiao J, Chen X, He Y, Yang L, et al. Protocol of the development of a core outcome set for ischemic stroke in clinical trials of Chinese medicine. Evid-based Complement Altern Med. 2020;2020:2649843.
26.
go back to reference Machielsen A, Iqbal N, Kimman ML, Sahnan K, Adegbola SO, Kleijnen J, et al. The development of a cryptoglandular anal fistula Core outcome set (AFCOS): an international Delphi study protocol. United European Gastroenterol J. 2020;8(2):220–6.CrossRef Machielsen A, Iqbal N, Kimman ML, Sahnan K, Adegbola SO, Kleijnen J, et al. The development of a cryptoglandular anal fistula Core outcome set (AFCOS): an international Delphi study protocol. United European Gastroenterol J. 2020;8(2):220–6.CrossRef
27.
go back to reference Qiu R, Li M, Zhang X, Chen S, Li C, Shang H. Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol. Trials. 2018;19(1):541.CrossRef Qiu R, Li M, Zhang X, Chen S, Li C, Shang H. Development of a core outcome set (COS) and selecting outcome measurement instruments (OMIs) for non-valvular atrial fibrillation in traditional Chinese medicine clinical trials: study protocol. Trials. 2018;19(1):541.CrossRef
28.
go back to reference Shi J, Gao Y, Si L, Ma X, Liu M, Liao X, et al. Determine what to measure and how to measure in clinical trials for the treatment of pressure injury: a protocol for the development of a core outcome set. Medicine. 2020;99(9):e19311.CrossRef Shi J, Gao Y, Si L, Ma X, Liu M, Liao X, et al. Determine what to measure and how to measure in clinical trials for the treatment of pressure injury: a protocol for the development of a core outcome set. Medicine. 2020;99(9):e19311.CrossRef
29.
go back to reference Mackenzie RM, Ells LJ, Simpson SA, Logue J. Development of a core outcome set for behavioural weight management programmes for adults with overweight and obesity: protocol for obtaining expert consensus using Delphi methodology. BMJ Open. 2019;9(2):e025193.CrossRef Mackenzie RM, Ells LJ, Simpson SA, Logue J. Development of a core outcome set for behavioural weight management programmes for adults with overweight and obesity: protocol for obtaining expert consensus using Delphi methodology. BMJ Open. 2019;9(2):e025193.CrossRef
30.
go back to reference Howie AH, Tingley K, Inbar-Feigenberg M, Mitchell JJ, Butcher NJ, Offringa M, et al. Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys. Trials. 2021;22(1):816.CrossRef Howie AH, Tingley K, Inbar-Feigenberg M, Mitchell JJ, Butcher NJ, Offringa M, et al. Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys. Trials. 2021;22(1):816.CrossRef
31.
go back to reference Niu B, Zhang M, Chua HZ, Li K, Zhang J. Treatment of chronic pulmonary heart disease with traditional Chinese medicine: a protocol for the development of a core outcome set (COS-TCM-CPHD). Evid-based Complement Altern Med. 2021;2021:5559883. Niu B, Zhang M, Chua HZ, Li K, Zhang J. Treatment of chronic pulmonary heart disease with traditional Chinese medicine: a protocol for the development of a core outcome set (COS-TCM-CPHD). Evid-based Complement Altern Med. 2021;2021:5559883.
Metadata
Title
Establishing a core outcome set for neurogenic bladder trials: study protocol for a scoping review and Delphi surveys
Authors
Yan Zhang
Yamin Chen
Mingming Niu
Yuanyuan Li
Jiaoyan Zhang
Li Zhang
Fangfang Wu
Qingyun Chen
Huijin Yu
Jinhui Tian
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06419-1

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue